The informative part of the release is how little of it changed. Each society ran its own review of the evidence for the seasonal respiratory vaccines, with support from the Vaccine Integrity Project, which sits inside the University of Minnesota's Center for Infectious Disease Research and Policy [6], and the resulting recommendations largely track what the CDC-liaised process produced before the upheaval [7]. The reviewers changed while the evidence stayed the same, and the output barely moved. That is the closest thing to a control this situation allows, and it is a weak one, because a single organisation supported all of the reviews [17]. This reads less like independent replication than one careful reading of the literature with several signatures attached.
The substantive change is obstetric. ACOG stretched the window for maternal RSV vaccination, which previously ran Sept. 1 to Jan. 31, out to March 1 [8], on chief medical officer Christina Davidson's account that recent RSV seasons have started later and run longer than what was previously seen [9]. Counted on a non-leap calendar, that is 153 days becoming 182, twenty-nine extra days, about 19 percent more window [16]. The announcement offers no surveillance behind "later and longer": no onset dates, no count of seasons compared, no magnitude. A timing rule justified by seasonal drift is only as sound as the drift estimate, and this one is asserted rather than shown.
The RSV product logic is where the guidance gets operationally awkward. The adult vaccine remains a single lifetime dose, because it is still unclear when or how often adults should be boosted [10], so a patient can be immunised during one pregnancy only. In later pregnancies the protection moves to the infant, in the form of monoclonal antibodies for babies 8 months or younger going into a first RSV season [11]. The American Academy of Pediatrics applies that same route to babies whose mothers were not vaccinated or whose status is unclear, and to high-risk children entering a second season [12].
Timing carries weight on the influenza side too: Sarah Nosal, president of the American Academy of Family Physicians, notes that the effect of flu vaccination wanes across a season, which makes October the better month [13]. This guidance is silent on who pays. Nothing in the announcement addresses coverage or reimbursement for the vaccines it recommends [18], and a recommendation a clinician endorses but a payer declines is a different object in a clinic than one both accept. Bruce Gellin, of the project's board of advisers, framed the exercise as holding a standard rather than replacing an agency: "Whatever happens to the federal vaccine policy process, we cannot lower that scientific standard" [15].
